Vaccines are Back

The last time I wrote about vaccines was two years ago – November 17, 2003, to be precise.1 That editorial crackled with frustration about the status of the most effective health intervention that has ever been invented:"Vaccines are unattractive targets for industry, underappreciated from the public health perspective, underfunded by basic research organizations, and treated with suspicion by the public."It's a pleasure to report that, two years later, there are the beginnings of a remark

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The last time I wrote about vaccines was two years ago – November 17, 2003, to be precise.1 That editorial crackled with frustration about the status of the most effective health intervention that has ever been invented:

"Vaccines are unattractive targets for industry, underappreciated from the public health perspective, underfunded by basic research organizations, and treated with suspicion by the public."

It's a pleasure to report that, two years later, there are the beginnings of a remarkable turnaround. Industry has rediscovered an appetite for developing vaccines. Research has been buoyed by some significant developments. And politicians, the media and the general public have developed a new regard for vaccines, engendered largely by panic at the prospect of a global flu epidemic. Scare stories about the dangers of vaccination are thin on the ground.

As reported on page 28, the pharmaceutical industry is embracing vaccines, with a string of recent takeovers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Richard Gallagher

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio